Biotech Values

[mcbio]

Here’s the 12/20/10 Goldman Sachs report on MNTA

I'm sorry but I'm having a hard time equating "low probability of a competitor approval in the next few years" (with respect to mLovenox) and "high probability of generic Copaxone approval" (without even considering the rest of the pipeline) to a $15 12-month price target.